Combination of gold nanoparticles with low-LET irradiation: an approach to enhance DNA DSB induction in HT29 colorectal cancer stem-like cells.
Cell Cycle
Cell Survival
Colorectal Neoplasms
/ pathology
Culture Media, Serum-Free
DNA
/ radiation effects
DNA Breaks, Double-Stranded
Dose-Response Relationship, Radiation
Gold
/ chemistry
HT29 Cells
Histones
/ metabolism
Humans
Metal Nanoparticles
/ chemistry
Neoplastic Stem Cells
/ radiation effects
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
Up-Regulation
X-Rays
Cancer stem-like cell
DNA DSBs
Gold nanoparticle
RBE value
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
20
06
2018
accepted:
11
10
2018
pubmed:
21
10
2018
medline:
29
1
2019
entrez:
21
10
2018
Statut:
ppublish
Résumé
High-linear energy transfer (high LET) irradiation has significant cytotoxic effects on different cancerous stem-like cells (CSLCs) such as colorectal CSLCs. A review of the literature has indicated that the presence of gold nanoparticles (GNPs) enables low-LET irradiation to produce highly non-homogeneous dose distributions like high-LET irradiation. The purpose of this study was to evaluate the radioresponsiveness of HT29 colorectal CSLCs under low-LET irradiation (X-ray) and in the presence of GNPs. Radioresponsiveness was evaluated using the ϒ-H2AX foci formation assay, the clonogenic assay, the cell cycle progression assay and analyses of radiobiological parameters. In the presence of GNPs, the survival fraction of HT29 CSLCs was significantly reduced and caused significant changes in the radiobiological parameters after irradiation. In addition, ϒ-H2AX assay showed that in the presence of GNPs, the persistent DNA double-strand breaks were significantly increased in irradiated HT29 CSLCs. The relative biological effectiveness value of GNPs with X-rays was about 1.6 for HT-29 CSLCs at the 10% of cell survival fraction (D Therefore, the combination of GNPs with X-ray irradiation has the potential to kill HT29 CSLCs greater than the X-ray alone, and may be considered as an alternative for high-LET irradiation.
Identifiants
pubmed: 30341685
doi: 10.1007/s00432-018-2769-3
pii: 10.1007/s00432-018-2769-3
doi:
Substances chimiques
Culture Media, Serum-Free
0
H2AX protein, human
0
Histones
0
Gold
7440-57-5
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
97-107Références
J Radiat Res. 1999 Dec;40 Suppl:1-13
pubmed: 10804988
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):241-50
pubmed: 10924995
Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):809-15
pubmed: 11172964
J Biol Chem. 2004 Jan 16;279(3):2273-80
pubmed: 14561744
Br J Cancer. 2003 Dec 15;89(12):2277-83
pubmed: 14676806
Biochem Biophys Res Commun. 2004 Jan 23;313(4):856-62
pubmed: 14706621
Am J Clin Oncol. 2004 Feb;27(1):24-8
pubmed: 14758129
BMC Bioinformatics. 2005 Mar 21;6:62
pubmed: 15780134
Radiat Res. 2006 Jan;165(1):59-67
pubmed: 16392963
J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85
pubmed: 17179479
Nucleic Acids Res. 2007;35(5):e36
pubmed: 17284459
In Vitro Cell Dev Biol. 1991 Dec;27A(12):900-6
pubmed: 1757394
J Radiat Res. 2008 May;49(3):203-10
pubmed: 18413977
J Clin Oncol. 2008 Jun 10;26(17):2839-45
pubmed: 18539962
Nature. 2009 Apr 9;458(7239):780-3
pubmed: 19194462
Br J Cancer. 2009 Jul 21;101(2):320-6
pubmed: 19568234
Int J Radiat Biol. 2009 Nov;85(11):1032-41
pubmed: 19895280
Mol Pharm. 2010 Feb 1;7(1):280-90
pubmed: 19994852
Br J Cancer. 2010 Apr 13;102(8):1265-75
pubmed: 20332776
Radiat Res. 2010 Jun;173(6):719-28
pubmed: 20518651
Int J Radiat Biol. 2010 Aug;86(8):682-91
pubmed: 20569192
Nanotechnology. 2010 Jul 23;21(29):295101
pubmed: 20601762
Mol Cancer. 2010 Jul 14;9:192
pubmed: 20630067
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1527-35
pubmed: 20637980
J Oncol. 2011;2011:null
pubmed: 20936110
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):531-9
pubmed: 21095075
Cancer Res. 2011 May 15;71(10):3676-87
pubmed: 21454414
Cancers (Basel). 2011 Mar;3(1):1232-52
pubmed: 21603589
Am J Physiol Gastrointest Liver Physiol. 2011 Nov;301(5):G929-37
pubmed: 21836060
Vet Comp Oncol. 2011 Sep;9(3):232-40
pubmed: 21848626
Radiother Oncol. 2011 Sep;100(3):412-6
pubmed: 21924786
Int J Cancer. 2012 Mar 1;130(5):991-1000
pubmed: 21935920
J Control Release. 2012 Apr 30;159(2):281-9
pubmed: 22227023
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1291-7
pubmed: 22245200
J Cancer Res Ther. 2011 Oct-Dec;7(4):399-407
pubmed: 22269399
Sci Rep. 2011;1:18
pubmed: 22355537
Neoplasia. 2012 Feb;14(2):150-8
pubmed: 22431923
Cancer Lett. 2012 Sep 28;322(2):139-47
pubmed: 22459349
BMC Cancer. 2012 Apr 04;12:139
pubmed: 22475227
Biomaterials. 2012 Jul;33(20):5107-14
pubmed: 22494888
J Control Release. 2012 Jul 20;161(2):164-74
pubmed: 22516097
PLoS One. 2012;7(6):e39069
pubmed: 22745705
J Mol Signal. 2012 Aug 06;7(1):11
pubmed: 22866952
Radiat Res. 2012 Aug;178(2):AV237-43
pubmed: 22870974
Radiother Oncol. 2012 Nov;105(2):258-65
pubmed: 23017870
Breast Cancer Res Treat. 2013 Jan;137(1):81-91
pubmed: 23160926
PLoS One. 2012;7(11):e50423
pubmed: 23185620
Cell Death Dis. 2013 Jan 31;4:e478
pubmed: 23370278
Acta Pharmacol Sin. 2013 Jun;34(6):793-804
pubmed: 23736004
Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):313-9
pubmed: 2394610
J Radiat Res. 2014 Jan 1;55(1):75-83
pubmed: 23955054
PLoS One. 2013 Oct 16;8(10):e75345
pubmed: 24146752
Cancers (Basel). 2011 Aug 15;3(3):3331-52
pubmed: 24212957
World J Gastroenterol. 2014 Jan 28;20(4):923-42
pubmed: 24574766
CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17
pubmed: 24639052
Int J Radiat Biol. 2014 Dec;90(12):1125-32
pubmed: 24882391
Cancer Cell Int. 2015 Jan 28;15(1):2
pubmed: 25685060
Mol Cancer. 2015 Sep 04;14:166
pubmed: 26338199
J Theor Biol. 2016 Apr 7;394:93-101
pubmed: 26807808
Front Oncol. 2016 Feb 12;6:23
pubmed: 26904502
Oncotarget. 2016 Jul 19;7(29):45112-45121
pubmed: 27129175
J Med Signals Sens. 2016 Apr-Jun;6(2):112-6
pubmed: 27186539
ACS Appl Mater Interfaces. 2016 Jul 20;8(28):17793-804
pubmed: 27348241
Int J Cancer. 2017 Jan 1;140(1):10-22
pubmed: 27389307
Int J Radiat Biol. 2017 Mar;93(3):315-323
pubmed: 27690719
Radiat Res. 1987 Aug;111(2):354-60
pubmed: 2819936
Nanomedicine. 2017 Jul;13(5):1653-1661
pubmed: 28285162
Sci Rep. 2017 Aug 24;7(1):9290
pubmed: 28839163
Int J Radiat Biol. 1994 Jan;65(1):7-17
pubmed: 7905912